OKYO Pharma Limited (OKYO)

Market Cap	52.90M
Revenue (ttm)	n/a
Net Income (ttm)	-6.70M
Shares Out	21.77M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,741
Open	2.21
Previous Close	2.32
Day's Range	2.21 - 2.43
52-Week Range	1.61 - 6.11
Beta	0.02
Analysts	Buy
Price Target	3.50 (+44.03%)
Earnings Date	n/a

About OKYO

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 17, 2022
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: OKYO

Analyst Forecast

According to 5 analysts, the average rating for OKYO stock is "Buy." The 12-month stock price forecast is $3.5, which is an increase of 44.03% from the latest price.

Price Target

$3.5

(44.03% upside)

Analyst Consensus: Buy